Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Forecast 2029: Size, Share, and Competitive Landscape
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Expected To Grow In Terms Of Size?
In recent times, the market size for the experimental new drug contract development and manufacturing organization (CDMO) has experienced substantial growth. The market, which is projected to increase from $5.53 billion in 2024 to $5.91 billion in 2025, is set to exhibit a compound annual growth rate (CAGR) of 7.0%. This significant expansion during the historical period is as a result of several factors including an escalated demand for early-stage clinical trials, the rise in outsourcing from pharmaceutical firms, growth in the development of biologics and complex molecules, enhanced regulatory support for expedited drug approval processes, and a heightened emphasis on cost-effectiveness and speed in bringing products to market.
The market size for Contract Development and Manufacturing Organizations (CDMO) dealing with the production of experimental novel drugs is set to witness robust expansion in the coming years. Its valuation is projected to escalate to $7.67 billion by 2029, with the Compound Annual Growth Rate (CAGR) calculated at 6.7%. Multiple factors fueling this growth in the forecast period include an enhanced emphasis on the development of rare and orphan drugs, escalating demand for consolidated preclinical-to-clinical services, rising complexity in the field of biologics and genetic treatment methods, burgeoning investments in small molecule innovation, and a surge in embracing virtual pharma business models. Key trends predicted in the forecast span include improvements in comprehensive drug development infrastructure, the inception of AI-powered clinical trial designs, strides in customised medicine production, progression in regulatory compliance technology, and the establishment of adaptable and module-based production facilities.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp
What Market Forces Are Contributing To The Growth Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?
The upward trend in clinical trials is predicted to stimulate the expansion of the investigational new drug contract development and manufacturing organization (CDMO) market. Clinical trials are meticulously planned research involving human subjects to test the safety and efficacy of medical treatments, procedures, or interventions under regulated conditions. The upsurge in clinical trials is primarily attributed to the escalating demand for innovative cures, with increasing instances of chronic and complex illnesses prompting pharmaceutical and biotechnology firms to create and test new treatments. Investigational new drug CDMOs facilitate clinical trials by simplifying the production and development of trial-ready drug formulations, ensuring a timely and compliant provision of investigational products for each study stage. For example, the Association of the British Pharmaceutical Industry, a UK trade association, reported in November 2023 that the annual count of industry-led clinical trials in the UK boosted by 4.3%, expanding from 394 in 2021 to 411 in 2022. Thus, the burgeoning clinical trials are fueling the advancement of the investigational new drug contract development and manufacturing organization (CDMO) market.
How Is The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segmented Across Key Categories?
The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product: Small Molecules, Large Molecules
2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations
3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services
4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides
2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics
What Key Trends Are Driving Growth In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?
Leading players in the investigational new drug contract development and manufacturing organization (CDMO) market are concentrating on creating strategic alliances to boost their development capabilities and expedite clinical entry. These strategic partnerships consist of formal collaborations between two or more companies striving to attain mutual goals, capitalizing on each other’s strengths, resources, or proficiency to obtain shared advantages while remaining separate entities. For instance, in August 2023, the Germany-based life science company Sartorius AG formed a partnership with Repligen Corporation, a life sciences company based in the US. The partnership was forged to introduce an integrated system that merges the BIOSTAT STR and XCell ATF technologies to intensify the upstream process. The intended aim of this partnership is to simplify biopharmaceutical production by improving efficiency and scalability. This move signifies Sartorius’ ongoing dedication to innovative bioprocessing solutions, underscoring its commitment to the progression of the biomanufacturing industry.
Who Are The Major Stakeholders Operating In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.
Access The Complete Report Here:
How Do Regional Dynamics Influence The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Performance?
North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25803&type=smp
Browse Through More Reports Similar to the Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market 2025, By The Business Research Company
Cell And Gene Therapy Contract Development And Manufacturing Organization Cdmo Global Market Report 2025
Biopharmaceuticals Contract Manufacturing Global Market Report 2025
Pharmaceutical Contract Packaging Global Market Report 2025
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
